Your browser is no longer supported. Please, upgrade your browser.
APTX Aptinyx Inc. daily Stock Chart
APTX [NASD]
Aptinyx Inc.
Index- P/E- EPS (ttm)-1.55 Insider Own1.30% Shs Outstand43.84M Perf Week-9.82%
Market Cap213.21M Forward P/E- EPS next Y-1.35 Insider Trans- Shs Float38.09M Perf Month12.78%
Income-55.40M PEG- EPS next Q-0.28 Inst Own64.20% Short Float2.69% Perf Quarter90.68%
Sales3.60M P/S59.23 EPS this Y-7.10% Inst Trans0.16% Short Ratio2.46 Perf Half Y25.00%
Book/sh2.79 P/B1.61 EPS next Y-8.00% ROA-45.80% Target Price- Perf Year17.80%
Cash/sh2.55 P/C1.76 EPS next 5Y- ROE-48.00% 52W Range1.60 - 5.28 Perf YTD31.58%
Dividend- P/FCF- EPS past 5Y- ROI-58.80% 52W High-16.63% Beta-
Dividend %- Quick Ratio27.10 Sales past 5Y- Gross Margin- 52W Low175.11% ATR0.41
Employees43 Current Ratio27.10 Sales Q/Q-11.10% Oper. Margin- RSI (14)53.38 Volatility8.56% 9.83%
OptionableNo Debt/Eq0.00 EPS Q/Q32.90% Profit Margin- Rel Volume0.55 Prev Close4.50
ShortableYes LT Debt/Eq0.00 EarningsMay 14 AMC Payout- Avg Volume415.60K Price4.40
Recom1.60 SMA201.26% SMA5011.31% SMA20028.69% Volume42,397 Change-2.18%
Jul-01-20Initiated SunTrust Buy $15
May-08-20Initiated William Blair Outperform
Apr-29-20Initiated H.C. Wainwright Buy $7
Sep-12-19Initiated Wedbush Outperform
Aug-13-19Downgrade JP Morgan Neutral → Underweight
Jun-20-19Initiated SVB Leerink Outperform $12
Jan-17-19Downgrade JP Morgan Overweight → Neutral
Nov-15-18Initiated Cantor Fitzgerald Overweight $40
Jul-16-18Initiated Leerink Partners Outperform $35
Jul-16-18Initiated JP Morgan Overweight $30
Jul-08-20 08:37AM  
Jul-07-20 12:51PM  
Jul-05-20 10:27PM  
Jun-26-20 08:37AM  
Jun-18-20 07:57AM  
Jun-16-20 08:37AM  
May-25-20 11:30AM  
May-20-20 12:00PM  
08:49AM  
May-18-20 08:19AM  
May-16-20 08:44AM  
May-14-20 05:15PM  
04:03PM  
May-07-20 12:30PM  
May-06-20 11:23AM  
May-04-20 12:24PM  
Apr-30-20 08:47AM  
Apr-28-20 09:00AM  
Apr-16-20 12:08PM  
Apr-03-20 12:00PM  
Apr-01-20 02:04PM  
Mar-30-20 05:45PM  
04:01PM  
03:00PM  
Mar-23-20 12:30PM  
Mar-18-20 04:01PM  
Mar-12-20 12:30PM  
Feb-19-20 08:37AM  
Jan-30-20 07:07AM  
Jan-18-20 05:09PM  
Jan-17-20 02:11PM  
Jan-14-20 04:01PM  
Jan-10-20 09:00AM  
07:13AM  
Jan-09-20 04:08PM  
Jan-08-20 05:28AM  
Dec-16-19 07:18AM  
Dec-12-19 07:07AM  
Dec-09-19 04:05PM  
Dec-05-19 06:58AM  
Nov-21-19 02:30PM  
Nov-19-19 09:40PM  
Nov-18-19 12:45PM  
Nov-15-19 03:15PM  
Nov-14-19 07:57AM  
Nov-13-19 08:00PM  
Nov-12-19 05:25PM  
04:01PM  
07:27AM  
Nov-11-19 08:29PM  
Nov-09-19 07:35AM  
Nov-05-19 10:32AM  
08:07AM  
Oct-31-19 07:40PM  
Oct-30-19 09:55AM  
Oct-29-19 01:42PM  
01:30PM  
01:07PM  
12:30PM  
Oct-28-19 06:27PM  
07:57AM  
Oct-25-19 11:15AM  
Oct-23-19 12:15PM  
Oct-22-19 05:20PM  
Oct-18-19 04:45PM  
Oct-15-19 02:45PM  
08:46AM  
Oct-14-19 02:20PM  
Oct-11-19 11:30PM  
Oct-10-19 02:55PM  
02:00PM  
Oct-08-19 09:00PM  
Oct-07-19 08:09PM  
Oct-03-19 09:09PM  
01:45PM  
Oct-02-19 06:59PM  
03:31AM  
Sep-30-19 07:03AM  
Sep-27-19 05:05PM  
Sep-26-19 03:15PM  
08:07AM  
Sep-25-19 08:50AM  
Sep-24-19 09:00PM  
Sep-23-19 05:27PM  
Sep-20-19 03:35PM  
Sep-16-19 05:06PM  
Sep-13-19 02:00PM  
Sep-11-19 04:30PM  
08:40AM  
Sep-09-19 06:35PM  
Sep-07-19 02:58PM  
Sep-06-19 01:15PM  
Sep-04-19 09:21PM  
07:27AM  
Aug-23-19 08:44AM  
Aug-21-19 10:01PM  
08:33AM  
Aug-13-19 03:55PM  
Aug-12-19 07:45AM  
06:33AM  
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase I clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc to develop a compound for the treatment of major depressive disorder. Aptinyx Inc. was founded in 2015 and is headquartered in Evanston, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sherman Rachel E.DirectorJan 22Buy4.792,17410,4132,174Jan 23 05:44 PM
Koppel AdamDirectorJan 14Buy3.003,333,3339,999,9995,558,425Jan 16 04:20 PM
ADAMS STREET PARTNERS LLC10% OwnerJan 10Buy3.001,000,0003,000,0001,465,716Jan 14 05:05 PM
RIEDEL NORBERT GCEO and PresidentJan 10Buy3.0035,000105,00035,000Jan 14 04:23 PM
HOMBACH ROBERT J.DirectorJan 10Buy3.0050,000150,000139,100Jan 14 04:21 PM
Gosebruch Henry ODirectorJan 10Buy3.0025,00075,000125,000Jan 14 04:19 PM
ENRIGHT PATRICK GDirectorJan 10Buy3.00166,667500,0013,356,746Jan 14 04:16 PM
ENRIGHT PATRICK GDirectorJan 10Buy3.0095,000285,00095,000Jan 14 04:16 PM
HOMBACH ROBERT J.DirectorNov 22Buy3.2450,000161,75089,100Nov 26 04:12 PM